Olmesartan medoxomil 1 is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, four related substances (impurities) were observed along with the final API. Those impurities were identified as olmesartan acid, 4-acetyl olmesartan, 5-acetyl olmesartan, and dehydro olmesartan. Present work describes the synthesis and characterization of all these four impurities.
Introduction
The presence of impurities, also called as, related substances in an active pharmaceutical ingredient (API) can have a significant impact on the quality and safety of the drug products. Therefore, it is necessary to study the impurity profile of any API and control it during the manufacturing of a drug product. As per the ICH guidelines any impurities, which are forming at a level of ≥ 0.10% with respect to the API should be identified, synthesized and characterized thoroughly. 1 Olmesartan medoxomil 1 [Benicar®, Sankyo pharma] is the latest angiotensin receptor antagonist 2, 3 approved by the FDA for the treatment of hypertension ( Figure 1 ). 4 The drug works by inhibiting the effects of angiotensin II, a potent vasoconstrictor and one of the key contributors to cardiovascular and renal disease. 5 During the process for the synthesis of 1, four unknown impurities were observed. However, as far as we are aware, the syntheses of these four Very recently, we have described an efficient, industrial scale synthesis of olmesartan medoxomil 1. 6 During the synthesis of 1, we came across many process related impurities and some of them were captured in our prior report. 7 To comprehend the complete impurity profile of olmesartan medoxomil 1 and to compare the extent of contamination of the impurities in 1, we have decided to synthesize all the possible impurities. The HPLC chromatogram, Figure 2 , shows the impurity profile of 1. Initially, 1 was subjected to LCMS to learn about the number of contaminants associated with it. Apart from the molecular ion peak of 1, four more peaks with distinct molecular ions were observed in LCMS (Figure 3 ). Based on the molecular ion peaks, the following four structures 2 -5 were proposed (Figure 4) . Although, the structure of impurity 2 has been already 
Results and Discussion
The synthesis of impurity 2, also known as olmesartan acid impurity, is described in Scheme 1. Olmesartan medoxomil 1 was subjected to basic hydrolysis using sodium hydroxide in methanol at ambient reaction conditions afforded the impurity 2 in good yield and 99% HPLC purity. The structure of 2 was confirmed by spectral analysis. The 4-acetyl impurity 3 has been synthesized according to the synthetic sequence shown in Scheme 2. Treatment of dicyanoimidazole 6 with methyl magnesium chloride in THF followed by acidic work up afforded the corresponding acetyl derivative 7, which on acid hydrolysis under reflux provided the corresponding acid 8. The imidazole acid 8 on esterification with methanol and HCl provided the methyl ester of 4-acetyl propyl imidazole carboxylic acid 9. The acetyl imidazole derivative 9 was then condensed with biphenyl derivative 13 in presence of potassium carbonate in refluxing acetone to provide the N-alkylated acetyl imidazole derivative 10, which on further hydrolysis using aqueous NaOH in acetone gave the sodium salt 11. Alkylation of 11 with 4-chloromethyl-5-methyl-1,3-dioxolen-2-one 9 14 provided the medoxomil ester 12. Finally, deprotection of trityl group in 12 with acetic acid afforded 4-acetyl impurity of olmesartan medoxomil 3.
The synthesis of 5-acetyl impurity 4 commenced from the N-alkylated imidazole derivative 15, which is one of the intermediates in the synthesis of 1 (Scheme 3). The Grignard reaction of 15 with excess moles of methyl magnesium chloride in anhydrous toluene afforded 5-acetyl derivative of N-alkylated imidazole 16, which on deprotection using acetic acid provided 5-acetyl impurity 4 in good yield and purity. The structure of 4 was confirmed by standard spectral analysis. Finally, all the impurities 2 -5 were individually co-injected with the API 1 in the HPLC and the HPLC data was compared with that of the API 1. As expected, all the impurities were matching with the impurity profile of 1.
Conclusions
We have demonstrated the synthesis and complete characterization of some of the critical impurities of olmesartan medoxomil 1. This investigation helped us to establish the impurity profile of 1.
Experimental Section
General. 1 H NMR spectra were recorded at 400 MHz Varian FT NMR Spectrometer. The chemical shifts are reported in δ ppm relative to TMS. The IR spectra were obtained using Perkin Elmer, Spectrum One FT IR spectrophotometer, with substances being pressed in a KBr pellet. The mass analyses have been performed on AB-4000 Q-trap LC-MS/MS mass spectrometer (MDS SCIEX, Applied Bio systems, California, USA). All the solvents and reagents were used without further purification. 
Synthesis of olmesartan acid impurity 2

Synthesis of 4-acetyl impurity 3 2-Propylimidazole-4-acetyl-5-carbonitrile (7)
. To a solution of 2-propylimidazole-4,5-dicarbonitrile (6, 25.0 g, 0.156 mol) in THF (250.0 mL) was added a solution of methyl magnesium chloride in tetrahydrofuran (24.5 %, 142.5 mL, 0.47 mol) at room temperature and stirred for 1-2 h. After completion of the reaction, the reaction mass was quenched with 10% acetic acid (315.0 mL) and the mixture was extracted with toluene (100.0 mL). Combined the organic layers were washed with 25% sodium chloride solution (3 x 125.0 mL). Solvent was distilled off under reduced pressure to obtain the title compound 7 as a residue (29.7 g, yield 80 %; purity by HPLC 94%); IR (KBr): 3166, 2235, 1678 cm -1 ; 1 H NMR (400 MHz, DMSO-d6) δ 0.9 (t, J = 7.5 Hz, 3H), 1.7-1.9 (m, 2H), 2.6 (s, 3H), 2. HCl (90.0 mL) was refluxed for 24 h. After cooling to room temperature was added water (100.0 mL) and the pH of the solution was adjusted to 4 using 10% sodium hydroxide solution (100.0 mL) and the precipitated solid was filtered. The filtrate was extracted with ethyl acetate (4 x 150.0 mL). The solvent was removed by vacuum distillation to get the crude material, which was recrystalized using cyclohexane (50.0 mL) to yield 8 (9.5 g, yield 22 %; purity by HPLC 91%); IR (KBr): 3394, 1696 cm 
Methyl-4-acetyl-2-propylimidazole-5-carboxylate (9).
A solution of 2-propylimidazole-4-acetyl-5-carboxylic acid (8, 20 .0 g, 0.102 mol) in CH3OH/HCl (246.0 mL, 0.612 mol) was stirred vigorously for 4h at room temperature. After completion of the reaction, methanol was distilled off completely. To the residue was added ethyl acetate (100.0 mL) followed by water (100.0 mL) and the resulting mixture was stirred for 10 minutes. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 60.0 mL). The combined the organic layers were washed with water (50.0 mL) and the resulting organic layer was dried over sodium sulphate. Removal of solvent under reduced pressure gave a residue, which was recrystallized in cyclohexane to provide 9 (15. 013 mol) in 40% aqueous acetic acid (300.0 mL) was heated at 55-60 °C for 1-2 h. The reaction mass was cooled to room temperature and diluted with water (100.0 mL). The precipitated solids were filtered off, and the filtrate was extracted with dichloromethane (550.0 mL). The organic layer was washed with a mixture of 5% aqueous sodium bicarbonate solution (100.0 mL) and 5% sodium chloride solution (450.0 mL). Removal of the solvent followed by isolation in cyclohexane (30.0 mL) gave the pure product 3 as a white solid (3.3 g, yield 48%; purity by HPLC 98%); IR (KBr),) 3062, 1823, 1717, 1446 cm 
Synthesis of impurity 4
A solution of 16 (10.0 g, 0.013 mol) in 40% aqueous acetic acid (300.0 mL) was heated at 55-60 °C for 1-2 h. The reaction mass was cooled to room temperature and diluted with water (100.0 mL). The precipitated solids were filtered and washed with 40% aqueous acetic acid (10.0 mL), and the filtrate was extracted with dichloromethane (550.0 mL). The organic layer was washed with a mixture of 5% aqueous sodium bicarbonate solution (100.0 mL) and 5% sodium chloride solution (450.0 mL). Removal of the solvent followed by isolation in cyclohexane (30.0 mL) 
Synthesis of dehydro olmesartan (5)
Compound 18. To a stirred solution of 17 (3.0 g, 0.043 mol) in toluene (9.0mL) was added water (0.83 mL, 0.005mol) and pTSA (0.27 g, 0.0025mol) and the resulting mixture was refluxed in a Dean-Stark reaction set up for 8-10 h. The solvent was distilled off completely at 60 °C to obtain the title compound 18 as a residue. The residue was further purified by column chromatography using 10% ethyl acetate in hexane to provide pure compound 18 as a white solid (1.3 g, yield 45%; purity by HPLC 96%); IR (KBr) 3060, 1823, 1706 cm -1 ; 1 H NMR (400 MHz, DMSO-d6) δ 0.9 (t, J = 7.6 Hz, 3H), 1.6-1.7 (m, 2H), 2.1 (s, 3H), 2.2 (s, 3H), 2.5 (t, J = 7. 
Dehydro olmesartan (5).
To a stirred solution of 18 (9.0 g, 0.11 mol) in 40% aqueous acetic acid (270.0 mL) was heated at 55-60 °C for 2-3 h. The reaction mass was cooled to room temperature and diluted with 5% sodium chloride solution (135.0 mL). The precipitated solids were filtered off and washed with 40% aqueous acetic acid (10.0 mL), and the filtrate was extracted with dichloromethane (270.0 mL). The organic layer was washed with a mixture of 5% aqueous sodium bicarbonate solution (100.0 mL) and 5% sodium chloride solution (100.0 mL). The solvent was removed under reduced pressure and the residue was isolated from 1:1 mixture of acetone and n-heptane (100.0 mL) to give the pure product 5 (5.6 g, yield 90%; purity by HPLC 98%); IR (KBr) 2928, 1824, 1714 cm 
